225 related articles for article (PubMed ID: 18223695)
1. The effect of administration order of BU and CY on engraftment and toxicity in HSCT mouse model.
Sadeghi B; Jansson M; Hassan Z; Mints M; Hägglund H; Abedi-Valugerdi M; Hassan M
Bone Marrow Transplant; 2008 May; 41(10):895-904. PubMed ID: 18223695
[TBL] [Abstract][Full Text] [Related]
2. Effect of altering administration order of busulphan and cyclophosphamide on the myeloablative and immunosuppressive properties of the conditioning regimen in mice.
Nilsson C; Forsman J; Hassan Z; Abedi-Valugerdi M; O'Connor C; Concha H; Jansson M; Hassan M
Exp Hematol; 2005 Mar; 33(3):380-7. PubMed ID: 15730862
[TBL] [Abstract][Full Text] [Related]
3. GVHD after chemotherapy conditioning in allogeneic transplanted mice.
Sadeghi B; Aghdami N; Hassan Z; Forouzanfar M; Rozell B; Abedi-Valugerdi M; Hassan M
Bone Marrow Transplant; 2008 Dec; 42(12):807-18. PubMed ID: 18820712
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of two conditioning regimens in treatment of leukemia by allogeneic hematopoietic stem cell transplantation].
Zhang GC; Zheng D; Guan XX; Luo SK; Li J; Peng AH; Tong XZ; Lai FZ; Tan EX; Hong WD
Ai Zheng; 2003 Jun; 22(6):620-3. PubMed ID: 12948413
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and toxicity of intravenous busulfan-based conditioning before allogeneic peripheral blood stem cell transplantation for leukemia].
Tong XZ; Xu DR; Zou WY; Li J; Luo SK; Peng AH; Zhang GC; Zheng D
Ai Zheng; 2007 Aug; 26(8):914-8. PubMed ID: 17697559
[TBL] [Abstract][Full Text] [Related]
6. Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients.
Westerhof GR; Ploemacher RE; Boudewijn A; Blokland I; Dillingh JH; McGown AT; Hadfield JA; Dawson MJ; Down JD
Cancer Res; 2000 Oct; 60(19):5470-8. PubMed ID: 11034090
[TBL] [Abstract][Full Text] [Related]
7. Depletion of donor-reactive cells as a new concept for improvement of mismatched bone marrow engraftment using reduced-intensity conditioning.
Prigozhina TB; Elkin G; Khitrin S; Slavin S
Exp Hematol; 2004 Nov; 32(11):1110-7. PubMed ID: 15539090
[TBL] [Abstract][Full Text] [Related]
8. Effects of cyclophosphamide and of busulfan on spleen colony-forming units and on hematopoietic stroma.
Fried W; Kedo A; Barone J
Cancer Res; 1977 Apr; 37(4):1205-9. PubMed ID: 321118
[TBL] [Abstract][Full Text] [Related]
9. Intestinal response to myeloablative chemotherapy in piglets.
Pontoppidan PL; Shen RL; Petersen BL; Thymann T; Heilmann C; Müller K; Sangild PT
Exp Biol Med (Maywood); 2014 Jan; 239(1):94-104. PubMed ID: 24304819
[TBL] [Abstract][Full Text] [Related]
10. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen.
Aggarwal C; Gupta S; Vaughan WP; Saylors GB; Salzman DE; Katz RO; Nance AG; Tilden AB; Carabasi MH
Biol Blood Marrow Transplant; 2006 Jul; 12(7):770-7. PubMed ID: 16785066
[TBL] [Abstract][Full Text] [Related]
11. Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT.
Cantoni N; Gerull S; Heim D; Halter J; Bucher C; Buser A; Tsakiris DA; Passweg J; Tichelli A; Stern M; Gratwohl A
Bone Marrow Transplant; 2011 Mar; 46(3):344-9. PubMed ID: 20548339
[TBL] [Abstract][Full Text] [Related]
12. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
Ulrickson M; Aldridge J; Kim HT; Hochberg EP; Hammerman P; Dube C; Attar E; Ballen KK; Dey BR; McAfee SL; Spitzer TR; Chen YB
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1447-54. PubMed ID: 19822305
[TBL] [Abstract][Full Text] [Related]
13. Modification of the Bu/Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring.
Mamlouk K; Saracino G; Berryman RB; Fay JW; Pineiro LA; Vance EA; White M; Sandler I; Agura ED
Bone Marrow Transplant; 2005 Apr; 35(8):747-54. PubMed ID: 15750611
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the effects of preconditioning regimens on hepatic veno-occlusive disease in mice after hematopoietic stem cell transplantation.
Qiao J; Fu J; Fang T; Huang Y; Mi H; Yang N; Chen C; Xu K; Zeng L
Exp Mol Pathol; 2015 Feb; 98(1):73-8. PubMed ID: 25533545
[TBL] [Abstract][Full Text] [Related]
15. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM
Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664
[TBL] [Abstract][Full Text] [Related]
16. Depletion of alloantigen-primed lymphocytes overcomes resistance to allogeneic bone marrow in mildly conditioned recipients.
Prigozhina TB; Elkin G; Gurevitch O; Morecki S; Yakovlev E; Khitrin S; Slavin S
Blood Cells Mol Dis; 2004; 33(3):238-47. PubMed ID: 15528138
[TBL] [Abstract][Full Text] [Related]
17. Effect of conditioning regimen on the outcome of bone marrow transplantation from an unrelated donor.
Kanda Y; Sakamaki H; Sao H; Okamoto S; Kodera Y; Tanosaki R; Kasai M; Hiraoka A; Takahashi S; Miyawaki S; Kawase T; Morishima Y; Kato S;
Biol Blood Marrow Transplant; 2005 Nov; 11(11):881-9. PubMed ID: 16275591
[TBL] [Abstract][Full Text] [Related]
18. [Alterations in coagulation in patients during transplant conditioning regimen before allogeneic hematopoietic stem cell transplantation].
Jiang Q; Huang XJ; Liu KY; Chen H; Chen YH; Gao ZY; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 Mar; 27(3):173-7. PubMed ID: 16792919
[TBL] [Abstract][Full Text] [Related]
19. [Application of low dose of fludarabine and cyclophosphamide combined with donor NK Cells as a non-myeloablative conditioning regimen for the haploidentical hematopoietic stem cell transplantation in mice].
Yu JP; Cao S; Xin N; An XM; Qi J; Ren XB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):1013-8. PubMed ID: 17956681
[TBL] [Abstract][Full Text] [Related]
20. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma.
Kim JG; Sohn SK; Chae YS; Yang DH; Lee JJ; Kim HJ; Shin HJ; Jung JS; Kim WS; Kim DH; Suh C; Kim SJ; Eom HS; Bae SH
Bone Marrow Transplant; 2007 Nov; 40(10):919-24. PubMed ID: 17846602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
